Bavituximab

Modify Date: 2024-01-05 12:16:54

Bavituximab Structure
Bavituximab structure
Common Name Bavituximab
CAS Number 648904-28-3 Molecular Weight N/A
Density N/A Boiling Point N/A
Molecular Formula N/A Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Bavituximab


Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer[1].

 Names

Name Bavituximab

 Bavituximab Biological Activity

Description Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer[1].
Related Catalog
Target

Phosphatidylserine (PS)[1]

In Vitro Bavituximab binds to exposed phosphatidylserine (PS) molecules via the serum protein, β2-glycoprotein 1 (β2GP1)[1]. Bavituximab binds PS to induces antibody-dependent cellular cytotoxicity, resulting in tumor vessel destruction[1]. Bavituximab (10 μg/mL; 48 h) binds to exposed phosphatidylserine (PS) via 10 μM Sorafenib inducing exposure in HUVEC and bEnd.3 cells[2].
In Vivo Sorafenib induces exposure of anionic phospholipids in tumor model in mice. Bavituximab (100 μg/mouse; i.v.; single dose; 48 h after Sorafenib treatment) traces phosphatidylserine exposure in vivo[2]. Animal Model: Mice bearing subcutaneous PLC/PRF/5, C3A, and Huh7 tumors[2] Dosage: 100 μg/mouse (Bavituximab/β2GP1) Administration: Intravenous injection single dose; 48 h after sorafenib treatment (100 mg/kg; p.o.; single dose) Result: Traced phosphatidylserine exposure in vivo in mice with tumors.
References

[1]. Digumarti R, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6.  

[2]. Cheng X, et al. Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Ann Surg Oncol. 2016 Dec;23(Suppl 5):583-591.  

 Chemical & Physical Properties

No Any Chemical & Physical Properties